Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$104.03 USD
+0.69 (0.67%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $104.14 +0.11 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BPMC 104.03 +0.69(0.67%)
Will BPMC be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BPMC
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Other News for BPMC
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Arcturus Therapeutics (ARCT) and Blueprint Medicines (BPMC)
Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Blueprint Medicines Corporation: A Strong Buy on Robust Clinical Data and Financial Health
Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Blueprint Medicines (BPMC)